GTx (GTXI)
GTx Revenues: 1.829M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GTXI Revenues Rankings
| Overall | 3rd percentile | 4269 of 4425 |
| Sector | 15th percentile | 396 of 470 in Healthcare |
| Industry | 27th percentile | 96 of 132 in Biotechnology |
GTXI Revenues Range, Past 5 Years
| Minimum | 0.935M | Jun 2010 |
| Maximum | 56.58M | Mar 2010 |
| Average | 5.546M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these GTXI related companies
GTXI News
GTx Announces Webcast of Corporate Presentation at Jefferies 2012 Global Healthcare Conference
May 29, 7:30AM Business Wire
May 29, 7:30AM Business Wire
$GTXI Earnings losses of $11.1M trumped by news that they've moved past FDA concerns and can initiate clinical studies http://stks.co/3jdH
about 21 days ago by abubnic
about 21 days ago by abubnic
$GTXI Downside Blowoff - 15 Minute Up Reversal - Green bar after 4 red bars
about 21 days ago by TradeIdeasQuant
about 21 days ago by TradeIdeasQuant
$GTXI Mentioned more than normal on StockTwits - Currently at 8 x average daily social activity
about 22 days ago by TradeIdeasQuant
about 22 days ago by TradeIdeasQuant
$GTXI 200 Day SMA Cross - Price crossed below 200 day SMA (3.6702). Confirmed by volume.
about 22 days ago by TradeIdeasQuant
about 22 days ago by TradeIdeasQuant
$GTXI 200 Day SMA Cross - Price crossed above 200 day SMA (3.6702). Confirmed by volume.
about 22 days ago by TradeIdeasQuant
about 22 days ago by TradeIdeasQuant
Listen to $GTXI Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3iVm
about 22 days ago by earningscast
about 22 days ago by earningscast
GTx (GTXI) Ramps Higher After FDA Removes Full Clinical Hold for Capesaris
May 08, 7:04AM Street Insider
May 08, 7:04AM Street Insider
GTx Announces Removal of Full Clinical Hold By FDA for Capesaris® In Advanced Prostate Cancer
May 08, 6:39AM Benzinga
May 08, 6:39AM Benzinga
Are $GTXI or the FDA required to issue a public statement regarding response letter in a specific time frame?
about 23 days ago by beezius
about 23 days ago by beezius
GTx, Inc. To Host First Quarter 2012 Financial Results Conference Call and Webcast
Apr 25, 7:30AM Business Wire
Apr 25, 7:30AM Business Wire
GTx (GTXI) Submits Complete Response to FDA for Capesaris Following Clinical Hold
Apr 04, 6:39AM Street Insider
Apr 04, 6:39AM Street Insider
GTx Announces Webcast of Corporate Presentation at the Cowen and Co. Annual Health Care Conference
Mar 02, 7:30AM Business Wire
Mar 02, 7:30AM Business Wire
GTx Announces Webcast of Corporate Presentation at the Citi 2012 Global Health Care Conference
Feb 24, 7:30AM Business Wire
Feb 24, 7:30AM Business Wire
Wedbush Cuts Price Target on GTX Inc. (GTXI), But Still Sees Some Value
Feb 21, 3:48PM Street Insider
Feb 21, 3:48PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GTXI | 3.14 | +0.07 | +2.28% | 192.80M |
| GTU | 57.54 | -0.86 | -1.47% | |
| GTSI | 7.73 | -0.01 | -0.13% | 74.69M |
| GTS | 17.69 | -0.10 | -0.56% | 505.77M |
| GTNA | 1.33 | +0.00 | +0.00% | 76.02M |
| GTN | 1.45 | +0.01 | +0.69% | 74.02M |
| GTLS | 66.92 | +2.78 | +4.33% | 1.901B |
| GTIM | 2.25 | -0.08 | -3.43% | 6.361M |
| GTI | 11.14 | +0.49 | +4.60% | 1.534B |
| GTE | 5.21 | +0.14 | +2.76% | 1.338B |
